Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I clinical study for its investigational product, STP705, which is focused on focal fat reduction (FFR). The study provides valuable insights into the potential of STP705 as a non-invasive treatment for reducing fat accumulation in specific body areas.
Phase I Clinical Study Design and Results
The Phase I trial for STP705 comprised three treatment cycles with administration intervals of 28 days. Eight subjects aged between 18 and 65 were randomly assigned to receive either STP705 or placebo lower abdominal injections following double-blind grouping. The results indicated that STP705 exhibited good safety and tolerability at all doses, concentrations, and volumes, with minimal occurrence of local skin reactions (LSR). Histological analysis of excised tissue samples further demonstrated that STP705 can induce adipocyte apoptosis, a key mechanism in fat reduction.
STP705’s Mechanism of Action and Potential Applications
STP705 is a siRNA (small interfering RNA) therapeutic that leverages dual-targeted inhibitory properties and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression. This innovative approach has the potential to address a range of therapeutic areas, including cholangiocarcinoma, non-melanoma skin cancer, and hypertrophic scarring, for which the product candidate has received multiple IND approvals from the US FDA and China’s National Medical Products Administration (NMPA).
Non-Invasive Fat Reduction and STP705’s Potential Impact
Non-invasive fat reduction procedures, such as cryolysis, radio frequency, and laser fat decomposition, have traditionally offered mild effects and required multiple treatments. STP705 is expected to offer a new choice for abdominal fat reduction and subcutaneous tissue remodeling, potentially revolutionizing the field of non-invasive body contouring.-Fineline Info & Tech
